There are currently 58 active clinical trials seeking participants for Neoplasms research studies. The states with the highest number of trials for Neoplasms participants are California, Texas, Florida and New York.
Hispanic Adapted and Culturally Relevant Exercising Together
NCT06018311
Recruiting
The purpose of this study is to determine the feasibility and effects of an adapted Exercising Together, a partnered resistance training program, on the physical and mental health of prostate cancer survivors and their informal caregiver. The Exercising Together program is designed to promote teamwork during supervised group exercise classes delivered remotely through videoconferencing software. The intervention period will be 3-months with a 3-month follow-up.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/19/2025
Locations: University of Arizona Cancer Center, Tucson, Arizona
Conditions: Neoplasms, Prostate Cancer, Exercise, Caregiver Burden, Cancer Survivors
Register for Updates
Endometrial Cell Collection With the PadKit
NCT06464107
Recruiting
All patients will be provided with a Preprogen Pad to be worn for 4-6 hours to collect cells shed by the endometrium. After the kit is returned to the Preprogen laboratory, a brief survey will be completed. Analysis will be conducted to determine if the PadKit™ can collect a sample of endometrial cells sufficient to differentiate between normal and atypical hyperplasia/malignant cells in blinded samples provided to the laboratory for analysis.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Jersey Shore University Medical Center, Neptune, New Jersey +1 locations
Conditions: Neoplasms
Register for Updates
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
NCT03911388
Recruiting
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
03/18/2025
Locations: Children's of Alabama, Birmingham, Alabama +2 locations
Conditions: Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms, Astrocytoma, Astrocytoma, Cerebellar, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Cerebellar PNET, Childhood, Cerebellar Neoplasms, Cerebellar Neoplasms, Primary, Cerebellar Neoplasm, Malignant, Cerebellar Neoplasm Malignant Primary, Neoplasm Metastases, Neoplasm Malignant, Neoplasms, Neuroepithelial, Neoplasms, Germ Cell and Embryonal, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Central Nervous System Neoplasms, Primary, Central Nervous System Neoplasms, Malignant, Nervous System Neoplasms, Neoplasms by Site, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Medulloblastoma Recurrent, HSV, Virus, Pediatric Brain Tumor, Nervous System Cancer, Primitive Neuroectodermal Tumor (PNET) of Cerebellum
Register for Updates
A Study of GSK5764227 in Participants With Advanced Solid Tumors
NCT06551142
Recruiting
The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of GSK5764227. The study will also see how the levels of GSK5764227 will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: GSK Investigational Site, Denver, Colorado +13 locations
Conditions: Neoplasms
Register for Updates
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
NCT03602157
Recruiting
The body has different ways of fighting infection and disease. No single way is perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances. Antibodies work by binding bacteria or substances, which stops them from growing and causing bad effects. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina
Conditions: Lymphoma, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Cutaneous Lymphoma, Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis, Cutaneous T Cell Lymphoma, Gray Zone Lymphoma
Register for Updates
PC001- A Study to Evaluate the Usability of PointCheck
NCT04448301
Recruiting
This a study about the usability of PointCheck a novel non-invasive technology for monitoring chemotherapy-induced neutropenia. The study will include patients with cancer visiting the outpatient hematology clinic for their standard of care chemotherapy administration. A final sample size of 90 oncologic outpatients will be enrolled and studied with the technology. The main objective is to evaluate the usability of PointCheck. Secondary outcomes include a preliminary assessment of PointCheck d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2025
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Neoplasms, Neutropenia
Register for Updates
Real World Registry for Use of the Ion Endoluminal System
NCT06004440
Recruiting
The primary objective of this study is to evaluate the performance of the Ion Endoluminal System with real-world use for pulmonary lesion localization or biopsy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Orlando Health Orlando Regional Medical Center, Orlando, Florida +15 locations
Conditions: Lung Cancer, Multiple Pulmonary Nodules, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: GSK Investigational Site, Birmingham, Alabama +129 locations
Conditions: Neoplasms
Register for Updates
Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings
NCT04931251
Recruiting
The financial burden, or financial toxicity (FT), of cancer is a consequential and growing problem, particularly for rural patients. It is important to improve our understanding of how financial navigation (FN) can reduce the material, psychological, and behavioral burden of costs associated with cancer care in both rural and non-rural community settings. The purpose of this study is to conduct a financial navigation program in 5 rural and 4 non-rural oncology practices in North Carolina and eva... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: NC Basnight Cancer Hospital, Chapel Hill, North Carolina +8 locations
Conditions: Neoplasms, Carcinoma
Register for Updates
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
NCT00349830
Recruiting
The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Carcinomas (Including Squamous Cell and Adenocarcinoma), Neoplasms
Register for Updates
Screening Strategies for People With a High Risk of Anal Cancer
NCT06628570
Recruiting
The goal of the proposed research is to 1) examine the performance of emerging screening methods for anal high-grade squamous intraepithelial lesion (aHSIL), a precancerous condition of anal cancer, among minorities with a high risk of anal cancer and 2) characterize DNA methylation, immunologic response, and social determinants associated with aHSIL.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
01/22/2025
Locations: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida +3 locations
Conditions: Neoplasms, HPV-Related Anal Squamous Cell Carcinoma
Register for Updates
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
NCT06706921
Recruiting
This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA RLT) at the West Los Angeles VA (WLA-VA) will be imaged with a baseline F-18 fluorodeoxyglucose positron emission tomography/computed tomography 18F-FDG PET/CT and a 18F-DCFPyL PET/CT (18F-DCFPyL (2-(3-{1-carboxy-5-\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: VA Greater Los Angeles Healthcare System, Los Angeles, California
Conditions: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer, Male Urogenital Diseases, Prostatic Diseases, Urogenital Diseases, Male, Genital Diseases, Male, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Genital Neoplasms, Male
Register for Updates